MENU
OCT 12, 2017 12:00 PM PDT

Detection of circulating tumour biomarkers using the FirePlex® Technology Platform

Speaker
  • General Manager - Platform Innovation, Abcam Inc.
    Biography
      Dr. Daniel Pregibon is the technical founder of Abcam's Firefly® Platform, serving as Abcam's General Manager of Platform Innovation. Dr. Pregibon received his Ph.D. from MIT's Department of Chemical Engineering under the guidance of Drs. Patrick Doyle (MIT) and Mehmet Toner (Harvard/MGH), where he discovered and co-developed Flow Lithography - the technology at the core of the Firefly® Platform. Prior to joining Abcam, he was the President and Chief Technology Officer at Firefly BioWorks, Inc., a start-up that explored the use of the platform for miRNA biomarker validation.

    Abstract

    The detection of circulating molecular biomarkers is useful for monitoring pathogenic processes and response to therapeutic intervention1,2. In cancer, genomic and proteomic biomarkers are used to assess tumour sub-type and stage, and determine patient stratification. Research has shown that using a combined signature of multiple biomarkers can better account for patient and epidemiological heterogeneity, and provide a more accurate indication of patient health2. In addition, the desire to leverage minimally-invasive samples has necessitated the development of technologies that can profile biomarkers directly from biofluids such as plasma, serum, and urine. To address this need, we developed the FirePlex Technology platform, which allows for the sensitive and accurate multiplexed detection of protein analytes or miRNAs directly from a wide array of biological samples. The platform uses patented, multi-functional hydrogel particles that allow for in-well multiplexing and panel design flexibility.

    For the detection of protein analytes, FirePlex immunoassays use high-performance matched antibody pairs that provide minimal cross-reactivity between individual analytes, up to 5 logs dynamic range, and single-digit pg/ml sensitivity, while requiring only 12.5 µl biofluid input. Similarly, the FirePlex miRNA assay can reliably detect miRNAs directly from as little as 10 µl of biofluid without the need for RNA purification. This assay utilizes single¬ step RT-PCR signal amplification with universal primers, thus leveraging PCR sensitivity while eliminating an independent reverse transcription step and mitigating amplification biases introduced by target¬-specific qPCR.  

    FirePlex assays are validated across a wide range of biological samples including plasma, serum, urine and cell culture supernatant. The 96-well plate assay format enables high-throughput sample screening with readout on standard flow cytometers, thereby omitting the need for complex and expensive dedicated instrumentation. Finally, the integrated FirePlex Analysis Workbench software enables rapid data analysis, visualization, and export, and includes key features such as standard curves as well as publication-quality heatmaps and graphs. 

    Here we present data from studies using the FirePlex Platform to profile miRNAs in cancer. Together, the combination of multiplexed, high¬-sensitivity assays with powerful bioinformatics tools enables rapid discovery and validation of biomarker signatures from liquid and solid specimens


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 12, 2017 12:00 PM PDT

    Detection of circulating tumour biomarkers using the FirePlex® Technology Platform


    Specialty

    Cancer Research

    Molecular Biology

    Immunology

    Laboratory Testing

    Cell Biology

    Molecular Diagnostics

    Microbiology

    Oncology

    Genomics

    Pcr/rt-Pcr/real-Time Pcr

    Cancer Diagnostics

    Biochemistry

    Gene Expression

    Biomarkers

    Genetics

    Geography

    North America77%

    Europe14%

    Asia9%

    Registration Source

    Website Visitors100%

    Job Title

    Medical Laboratory Technician28%

    Clinical Laboratory Scientist17%

    Medical Doctor/Specialist17%

    Executive17%

    Facility/Department Manager11%

    Student6%

    Marketing/Sales6%

    Organization

    Life Science Company14%

    Hospital14%

    Ambulatory Care14%

    Clinical Laboratory14%

    Media9%

    Academic Institution9%

    Biotech Company9%

    Research Institute5%

    Other5%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more